Patients and Methods: Patients had one or more of the following: a retroperitoneal mass greater than or equal to 10 cm in diameter; mediastinal or supraclavicular mass greater than or equal to 5 cm in diameter; at least 20 lung metastases (any size); liver, bone, or brain metastases; and serum beta human chorionic gonadotropin (beta HCG) greater than or equal to 10,000 IU/L or alfa fetoprotein (AFP) greater than or equal to 1,000 IU/L. A total of 380 patients were accrued between May 1990 and June 1994 into this joint Medical Research Council (MRC)/European Organization for Research and Treatment of Cancer (EORTC) trial; of these, nine patients were deemed ineligible.

Results: There was no significant difference between the two arms in the proportion of patients who achieved a complete response (CR) with chemotherapy alone, ie, 79 of 185 assessable patients (57%) with BEP/EP and 72 of 186 (54%) with BOP/VIP-B (P = 0.687). With a median follow-up of 3.1 years (maximum, 5.8), a total of 107 patients (28%) had progressive disease. There was no significant difference in time to first disease progression, or failure-free or overall survival between the two arms (P = 0.21, 0.101, and 0.190, respectively). The 1-year failure-free survival rates for BEP/EP and BOP/VIP-B were 60% (95% confidence interval [CI], 53% to 67%) and 53% (95% CI, 47% to 61%). Grade 3 or 4 myelosuppression, febrile neutropenia, and weight loss were more pronounced with BOP/VIP-B than with BEP/EP, and there were more toxic deaths with BOP/VIP-B than BEP/EP(18 [9%] v nine [5%]).

Conclusion. The intensive BOP/VIP-B therapy was associated with more toxicity, but there wets no evidence of an improvement in response rate or survival compared with treatment with BEP/EP. (C) 1998 by American Society of Clinical Oncology.